



Artisan Value Fund

QUARTERLY
Commentary

Investor Class: ARTLX | Advisor Class: APDLX | Institutional Class: APLHX

As of 30 September 2021

For Financial Advisor Use Only. Not for Distribution to the Public.

Investment Process

We seek to invest in companies that are undervalued, in solid financial condition and have attractive business economics. We believe that companies with these characteristics are less likely to experience eroding values over the long term.

Attractive Valuation

We value a business using what we believe are reasonable expectations for the long-term earnings power and capitalization rates of that business. This results in a range of values for the company that we believe would be reasonable. We generally will purchase a security if the stock price falls below or toward the lower end of that range.

Sound Financial Condition

We prefer companies with an acceptable level of debt and positive cash flow. At a minimum, we seek to avoid companies that have so much debt that management may be unable to make decisions that would be in the best interest of the companies' shareholders.

Attractive Business Economics

We favor cash-producing businesses that we believe are capable of earning acceptable returns on capital over the company's business cycle.

Team Overview

Everyone on the team functions as a generalist with respect to investment research and the entire team works together on considering potential investments.

Portfolio Management



Thomas A. Reynolds IV
Portfolio Manager



Daniel L. Kane, CFA
Portfolio Manager



Craig Inman, CFA
Portfolio Manager

Investment Results (%)

As of 30 September 2021	Average Annual Total Returns						
	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTLX	-1.33	17.80	41.36	11.68	12.28	12.54	8.17
Advisor Class: APDLX	-1.28	17.89	41.53	11.88	12.46	12.65	8.24
Institutional Class: APLHX	-1.28	17.94	41.61	11.95	12.54	12.81	8.34
Russell 1000® Value Index	-0.78	16.14	35.01	10.07	10.94	13.51	7.68
Russell 1000® Index	0.21	15.19	30.96	16.43	17.11	16.76	10.39

Source: Artisan Partners/Russell. Returns for periods less than one year are not annualized. Class inception: Investor (27 March 2006); Advisor (1 April 2015); Institutional (26 July 2011). For the period prior to inception, each of Advisor Class and Institutional Class's performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor or Institutional Class and each share's respective returns during that period would be different if such expenses were reflected.

Expense Ratios (% Gross/Net)	ARTLX	APDLX	APHLX
Semi-Annual Report 31 Mar 2021 ¹	1.04/—	0.96/0.88 ^{2,3}	0.83/—
Prospectus 30 Sep 2020 ³	1.09/—	0.93/0.89 ²	0.83/—

¹Unaudited, annualized for the six-month period. ²Net expenses reflect a contractual expense limitation agreement in effect through 31 Jan 2022. ³See prospectus for further details.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.454.1770 for current to most recent month-end performance.



Investing Environment

US equities hit all-time highs in Q3 before coming under pressure in the final month of the quarter due to concerns about persistent supply chain disruptions feeding into inflation and input costs. These worries were also evidenced by a backup in interest rates with the yield on the 10-year Treasury note jumping over 20bps in the final week of the quarter. The late-quarter pullback resulted in the Russell 1000® Value Index returning -0.78% in Q3. Quarterly returns by sector were mixed, with financials, real estate and utilities finishing higher. The materials, industrials and consumer sectors were lower due to concerns about input cost pressures.

Stocks have continued to trade on sentiment around COVID-19 trends. Throughout the course of the pandemic over the past 18 months, market sentiment has oscillated between the so-called pandemic winners—many of which are in growth areas such as technology and e-commerce—to the economic reopening plays, such as travel and hospitality. The latter group rallied from November 2020 into the first half of 2021 on the vaccine rollout. But performance patterns reverted with growth stocks leading in July and August as the delta variant swept through the US. When the delta wave crested in September, outperformance switched back to value, though rising interest rates and energy prices also likely factored into value's late-quarter run.

Rather than attempting to forecast the pandemic and position the portfolio for a particular outcome, we have instead endeavored to create a diversified portfolio of financially sound, cash-producing businesses that are selling at attractive prices and not dependent on a specific macro scenario. We own a mix of businesses—some have benefited and some have lost due to COVID. For example, several of our technology-oriented holdings, including Alphabet and Facebook, which are actually classified within the communication services sector, performed well when the pandemic accelerated ongoing shifts related to remote work arrangements, online shopping and content consumption that are driving growth in e-commerce, cloud computing and digital advertising. These popular mega-cap FAANG stocks may seem odd fare for value managers, but they reflect our benchmark-agnostic, opportunistic value investment style focused on identifying discounts to intrinsic value, rather than just relying on statistical cheapness. Estimates of intrinsic value require a holistic assessment of a company's economic moat, the growth and durability of its cash flows, and as always a consideration of the risks and potential range of outcomes. We think you would be hard-pressed to find companies better positioned for the next decade than Alphabet and Facebook. Alphabet dominates online search, and Facebook leads the social media landscape, with its multiple social networks (e.g., Facebook Groups, Facebook Marketplace, Instagram Reels and WhatsApp). The two companies command large market shares within the digital advertising space that continues to grow at a double-digit annual pace versus the GDP-like growth rate of traditional advertising.

On the other side of the ledger, companies hurt by COVID early in the pandemic were Airbus, an aerospace manufacturer; Marriott, a hotel operator; and Compass Group, a food service provider. We opportunistically added all three names to the portfolio in March-April of 2020 when the stocks sold off sharply. We believed their businesses would gradually recover as the economy reopened and patterns of

travel, restaurant dining and business activity returned to some semblance of normal. These holdings performed well in the pandemic reopening trade. Their subsequent returns in recent months reflect that trade's slowing momentum as virus variants surged globally and rising uncertainty weighed on economic growth expectations. We remain confident in these businesses. They are leaders in their respective industries with wide moats and superior business economics. Each is led by a battle-tested management team we believe is executing well on its appropriately set strategy to deliver shareholder value. They are carefully and wisely financed, and they have undemanding valuations based on normalized earnings power. These examples illustrate our opportunistic nature. We welcome periods of volatility as our odds of finding investments which meet our margin of safety criteria increase when markets shift from risk-seeking to risk-fearing modes. We seek to use fear and uncertainty to our advantage, coupled with a long-term time horizon, to generate excess returns across the market cycle.

Performance Discussion

Our portfolio modestly trailed its benchmark in Q3, owing to select health care and industrials holdings. But given our portfolio return can diverge from the index's by 1% or more in any given day, there may not be much insight to be gained from assessing relative performance by stopping the clock on September 30. We believe there's more value to be gained by stepping back and looking at our longer term performance over the one-, three- and five-year time frames, which stack up favorably against the Russell 1000® Value Index.

Our weakest Q3 performers included FedEx and Fresenius Medical Care. Shares of FedEx, a global shipping and logistics firm, were held back by disappointing business results as labor cost headwinds and air network disruptions overshadowed solid top-line trends. We think the company should be able to overcome these near-term issues. Importantly, FedEx has strong pricing power as it operates in a consolidated global shipping industry. In September, the company announced it would increase its shipping rates by an average of 5.9% across most of its services, which is the first time in several years that its annual increase would exceed 5.0%. The industry's renewed pricing discipline is a welcome change, reflecting a broader commitment to earn better returns on invested capital. FedEx is also closer to fully integrating TNT, a European-focused parcel company it acquired in 2016. The market is beginning to incorporate a higher probability FedEx will fully integrate TNT, which will provide a significant boost to profits. The stock now trades at a near-trough multiple of less than 12X 2022 earnings, so we added to our position on weakness.

Fresenius Medical is a vertically integrated provider of dialysis equipment and services, reaching the large and growing global population of chronic kidney disease patients. The company has experienced headwinds related to the pandemic, most notably due to the higher mortality rates found among dialysis patients. However, the company is a global market-share leader in terms of both supplying dialysis equipment and treating dialysis patients, affording it a natural competitive advantage. Due to the relative stability of the business model, Fresenius carries more leverage on its balance sheet than we typically prefer, but it has steadily reduced its debt burden given strong and stable cash flows despite the ongoing industry

volatility. Further, management has indicated its intention to reduce capital intensity as it deploys an in-home solution for patients. Earnings and cash flow have steadily climbed for the better part of the last decade. We anticipate the business will continue to grow longer term and will benefit from the secular growth of its end markets.

Among our top Q3 contributors were Blackstone and Morgan Stanley. Investment stalwart Blackstone's virtuous cycle is in full swing. Throughout Blackstone's history, excellent investment performance and capital protection have allowed the firm to increase fundraising in existing verticals as well as launch new endeavors. Historically, less than 10% of assets under management mature in any given year, and that number should move lower with continued growth in perpetual capital vehicles. Blackstone's A+ rated balance sheet and capital-light model are the backbone of its 85% of cash flow distribution policy via a variable quarterly dividend. In short, this is a long-duration fee stream and robust capital-raising engine.

Morgan Stanley, a leading global financial services company, came into the portfolio in late 2020 as a result of its purchase of E*TRADE. The acquisition is a great fit for Morgan Stanley's wealth management platform and provides a considerable amount of non-interest-bearing deposit funding. James Gorman, chairman and CEO, has steadily de-risked the business by adding less volatile fee streams to complement its leading positions in cyclical businesses such as advisory, equities and FICC (fixed income, currencies and commodities). We believe the company will prove its resiliency and value over the long term.

Portfolio Activity

We initiated two new positions in Q3, adding Philips and Discovery. After exiting more consumer-focused businesses such as TV and lighting over the past decade, Philips has become a health care technology company operating across three main areas: diagnosis and treatment, connected care and personal health. The company primarily competes with Siemens and GE. Our opportunity came after shares fell on market fears regarding potential litigation in relation to its sleep division. In its first-generation CPAP machine for sleep apnea, there have been reported cases of degrading foam that can expose users to harmful particles. The company has instituted a recall offering to swap out the device or repair the existing machine. The news resulted in the company losing 10 billion euros in market cap, which seems overdone. The sleep division is a small part of the overall business—which we do not believe is going to zero. The company has a large installed base of diagnostic equipment (e.g., MRI/PET/CT/ultrasound scanners) that offers a high recurring stream of software-like maintenance revenues. This is a sticky business as medical providers are reluctant to switch over to competitors. So, the market's fears about headlines allowed us to purchase a high-quality medical technology business at an undemanding 16X multiple on CY2021 earnings.

Discovery is a media company that distributes content across US and international networks, such as HGTV, Discovery, TLC, Food Network and Animal Planet, among others, as well as its streaming service Discovery+. The company's large collection of lower budget, unscripted programming is highly popular. The company has three share classes. We hold the C share, which doesn't have voting rights and trades at a discount to the A and B share classes with voting

rights, but all three will be treated equally when collapsed into a single class in the planned merger with WarnerMedia. The merger—slated to close in Q2 2022—will combine Discovery's content with WarnerMedia's HBO, potentially making it the third-largest streaming company behind Netflix and Disney. We like the outlook of this merger as the new combined entity will have a good mix of content that should attract viewers. Discovery has already had significant success with rolling out Discovery+ as it had better than expected subscribership. Further, Discovery's shares are priced as a legacy media asset in decline, but we see significant upside given how the market values Netflix and Disney. However, we sized the position on the smaller end given the risks around integrating the businesses.

Our sales included Abbvie, a biopharmaceutical company, and Oracle, an enterprise software provider. Abbvie was a smaller position in the portfolio. We had concerns about its capital allocation and a stretched balance sheet, so we chose to move on. Our investment campaign in Oracle came to an end after nearly a decade of ownership as our patience in its transition to the cloud was rewarded. We exited our position as shares reached our estimates of fair value. We used the proceeds of these sales to fund our purchases of Philips and Discovery.

Perspective

While we typically discuss only a few holdings in each of our quarterly letters—choosing a few contributors and a few detractors—long-term portfolio performance is almost always driven by participation across sectors and industries. The portfolio isn't designed to be a one-trick pony. Rather than try to hit a few home runs, our goal is to get as many base hits as possible. Looking back at our results over the past 18 months, or roughly when the pandemic began, we see strong contributions to absolute returns up and down the portfolio. To put it in perspective, we had 30 holdings that each contributed at least 100bps to the portfolio's total return over this time frame. These results are closely tied to what we call the conglomerate concept. We think of our portfolio as a conglomerate. If we offered you the choice between only two portfolios: our conglomerate or the index, wouldn't you choose the one that is better, safer and cheaper? By doing our job and following our bottom-up process, we believe our collection of businesses should compare favorably against those in the index on the dimensions of business economics, financial condition and importantly, asking price.

For more information: Visit www.artisanpartners.com | Call 800.454.1770

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.454.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Value securities may underperform other asset types during a given period.

The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

This summary represents the views of the portfolio managers as of 30 Sep 2021. Those views may change, and the Fund disclaims any obligation to advise investors of such changes. For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The holdings mentioned above comprised the following percentages of the Fund's total net assets as of 30 Sep 2021: Alphabet Inc 6.5%, Facebook Inc 2.1%, Airbus SE 3.0%, Marriott International Inc 2.5%, Compass Group PLC 3.0%, FedEx Corp 3.1%, Fresenius Medical Care AG & Co KGaA 1.8%, Blackstone Inc 2.5%, Morgan Stanley 3.7%, Koninklijke Philips NV 2.0%, Discovery Inc 1.7%. Securities named in the Commentary, but not listed here are not held in the Fund as of the date of this report. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities. All information in this report, unless otherwise indicated, includes all classes of shares (except performance and expense ratio information) and is as of the date shown in the upper right hand corner. This material does not constitute investment advice.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell[®] is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2021 Artisan Partners. All rights reserved.

Not FDIC Insured | No Bank Guarantee | May Lose Value

For Financial Advisor Use Only. Not for Distribution to the Public.

